GPBAR1 and type 2 diabetes mellitus: Although the hypothesis that BAs may activate TGR5 to modulate human intestinal GLP-1 release and glucose homoeostasis remains to be further understood, the TGR5 signaling pathway may represent a target that may provide a highly promising strategy for the treatment of T2DM.